Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Hartman vREIT XXI, Inc. filed its annual report for the fiscal year ending 2026, detailing its portfolio of commercial real estate assets and operational performance. The report focuses on rental income stability, property management efficiencies, and the company's liquidity position as a non-traded real estate investment trust.
Emergent BioSolutions reported total assets of $995.2 million as of September 30, 2026, a decrease from $1,318.6 million at year-end 2025. The company is navigating significant debt obligations under a new 2026 Term Loan Agreement and is focused on its medical countermeasure (MCM) contracts with the U.S. government and the commercial performance of NARCAN Nasal Spray.
Tevogen $36M Debt Financing with The Patel Family, LLP
Tevogen Inc. amended its unsecured line of credit with The Patel Family, LLP, extending the borrowing period to May 31, 2029, and fixing the share price for debt repayment at $7.40 per share. Following the amendment, the company issued approximately 1.02 million shares to repay the entire $7.4 million outstanding principal balance and accrued interest, effectively eliminating its current debt liabilities.
Apple reported record Q4 revenue of $114.5 billion, up 12%, driven by iPhone and Mac growth despite significant memory cost headwinds and supply constraints.
Travere achieved record quarterly revenue of $220.2 million, driven by Filspari's expansion into FSGS, though management faces a CEO transition and increased competition in the IgA nephropathy market.
Aspen Neuroscience 10% Owner ARCH Venture Fund X L.P. Buys $20M of Stock
ARCH Venture Fund X L.P., 10% Owner, bought 1,333,333 shares of Aspen Neuroscience, Inc. at $15.00 a share, worth $20M in total on Nov 2, 2026. Shares held after the trade: 1,200,000.
Aspen Neuroscience 10% Owner ARCH Venture Partners XIV L.P. Buys $18M of Stock
ARCH Venture Partners XIV L.P., 10% Owner, bought 1,200,000 shares of Aspen Neuroscience, Inc. at $15.00 a share, worth $18M in total on Nov 2, 2026. Shares held after the trade: 1,200,000.
Hamilton Lane Venture Capital & Growth Fund Insider Hamilton Lane Advisors LLC Buys $36.5M of Stock
Hamilton Lane Advisors LLC bought 1,824,686 shares of Hamilton Lane Venture Capital & Growth Fund at $12.99 to $20.50 a share (average $20.02) in 2 transactions, worth $36.5M in total between Jul 28, 2025 and Oct 29, 2026. Shares held after the trade: 2,396,201 (+247.8%).
CrowdStrike Holdings President and CEO George Kurtz Sells $5.05M of Stock
George Kurtz, President and CEO, sold 19,800 shares of CrowdStrike Holdings, Inc. at $246.13 to $267.66 a share (average $255.10) in 29 transactions, worth $5.05M in total between Oct 29, 2026 and Oct 30, 2026. Shares held after the trade: 7,341,704 (-0.0%).
CrowdStrike Holdings President and CEO George Kurtz Sells $52.3K of Stock
George Kurtz, President and CEO, sold 200 shares of CrowdStrike Holdings, Inc. at $261.60 a share, worth $52.3K in total on Oct 30, 2026. Shares held after the trade: 7,341,504 (-0.0%).
CME Group Sr MD Chief Commercial Officer Julie Winkler Sells $3.08M of Stock
Julie Winkler, Sr MD Chief Commercial Officer, sold 10,079 shares of CME Group Inc. at $305.15 a share, worth $3.08M in total on Nov 2, 2026. Shares held after the trade: 21,482 (-31.9%).
Nurix Therapeutics CFO Houte Hans van Sells $74.5K of Stock
Houte Hans van, CFO, sold 2,834 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $74.5K in total on Oct 30, 2026. Shares held after the trade: 47,514 (-5.6%).
Nurix Therapeutics CLO Christine Ring Sells $104K of Stock
Christine Ring, CLO, sold 3,957 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $104K in total on Oct 30, 2026. Shares held after the trade: 15,335 (-20.5%).
Nurix Therapeutics CSO Gwenn Hansen Sells $143K of Stock
Gwenn Hansen, CSO, sold 5,409 shares of Nurix Therapeutics, Inc. at $26.28 to $26.80 a share (average $26.42) in 2 transactions, worth $143K in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 123,452 (-1.2%).
AerCap Holdings General Counsel Vincent Drouillard Sells $1.58M of Stock
Vincent Drouillard, General Counsel, sold 10,000 shares of AerCap Holdings N.V. at $158.14 a share, worth $1.58M in total on Oct 29, 2026. Shares held after the trade: 81,623 (-10.9%).
Gilead Sciences Chairman & CEO Daniel Patrick O'Day Sells $5.33M of Stock
Daniel Patrick O'Day, Chairman & CEO, sold 30,881 shares of Gilead Sciences, Inc. at $167.40 to $175.25 a share (average $172.57) in 6 transactions, worth $5.33M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 551,683 (-0.4%).
Pitney Bowes President & CEO Kurt James Wolf Sells $3.33M of Stock
Kurt James Wolf, President & CEO, sold 201,517 shares of Pitney Bowes Inc at $16.23 to $17.45 a share (average $16.54) in 4 transactions, worth $3.33M in total between Oct 29, 2026 and Nov 2, 2026. Shares held after the trade: 73,184 (-15.6%).
Peuch Olivier Le, CEO, sold 25,000 shares of Slb Limited at $52.90 a share, worth $1.32M in total on Nov 2, 2026. Shares held after the trade: 1,246,328 (-2.0%).
Fortive VP - CAO Christopher M. Mulhall Sells $1.71M of Stock
Christopher M. Mulhall, VP - CAO, sold 26,055 shares of Fortive Corp at $65.56 to $65.57 a share (average $65.56) in 2 transactions, worth $1.71M in total on Oct 30, 2026. Shares held after the trade: 15,597 (-34.2%).
Fortive SVP - CLO Peter C. Underwood Sells $3.13M of Stock
Peter C. Underwood, SVP - CLO, sold 48,442 shares of Fortive Corp at $64.60 a share, worth $3.13M in total on Oct 30, 2026. Shares held after the trade: 79,118 (-38.0%).
Rimini Street EVP & Chief Revenue Officer Steven Hershkowitz Sells $211K of Stock
Steven Hershkowitz, EVP & Chief Revenue Officer, sold 42,482 shares of Rimini Street, Inc. at $4.98 a share, worth $211K in total on Nov 2, 2026. Shares held after the trade: 186,992 (-18.5%).
Rush Street Interactive Insider Thomas Winter Buys $118K of Stock
Thomas Winter bought 10,000 shares of Rush Street Interactive, Inc. at $11.83 a share, worth $118K in total on Nov 2, 2026. Shares held after the trade: 30,497 (+48.8%).
BioMarin achieved record $1B+ quarterly revenue but lowered full-year guidance due to $70M in international order timing shifts and Middle East geopolitical headwinds, despite strong underlying demand and accelerated Amicus cost synergies.
Medpace Holdings General Counsel & Corp. Secy. Stephen P. Ewald Sells $859K of Stock
Stephen P. Ewald, General Counsel & Corp. Secy., sold 1,245 shares of Medpace Holdings, Inc. at $690.00 a share, worth $859K in total on Oct 29, 2026. Shares held after the trade: 19,098 (-6.1%).
Northern Trust Insider Robert Edward Moritz Jr. Buys $39.9K of Stock
Robert Edward Moritz Jr. bought 236 shares of Northern Trust Corp at $169.07 a share, worth $39.9K in total on Oct 30, 2026. Shares held after the trade: 8,636 (+2.8%).
Cytokinetics President & CEO Robert I. Blum Sells $471K of Stock
Robert I. Blum, President & CEO, sold 7,500 shares of Cytokinetics Inc at $62.81 a share, worth $471K in total on Nov 2, 2026. Shares held after the trade: 278,544 (-2.6%).
Backblaze delivered a strong Q3 beat and raise, driven by 47% B2 revenue growth and significant AI infrastructure momentum, including early data loading from a major NeoCloud customer.
Etsy Director Josh Silverman Sells $3.93M of Stock
Josh Silverman, Director, sold 42,689 shares of Etsy Inc at $88.70 to $92.13 a share (average $92.03) in 2 transactions, worth $3.93M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 221,117 (-15.8%).
EverQuote delivered record Q3 results with 25% revenue growth, driven by a 70% surge in the home vertical and aggressive AI integration across its marketplace and internal engineering workflows.